Julie Brahmer, MD

Professional Titles

• Co-Director of the Upper Aerodigestive Department within the Bloomberg~Kimmel Institute for Cancer Immunotherapy
• Co-Director, Cancer Immunology Program
• Director, Thoracic Oncology

Primary Academic Title

Professor of Oncology

Background

Centers and Institutes

• Bloomberg~Kimmel Institute for Cancer Immunotherapy
• Sidney Kimmel Comprehensive Cancer Center

Clinical Trial Keywords

Phase 1; mesothelioma; lung cancer

Videos

• Harnessing The Immune System to Fight Cancer

• Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy

• Immunotherapy and Antibodies | Slaying Lung Cancer

• The Bloomberg~Kimmel Institute: Immunotherapy - Game Changer, Game Challenge

Recent News Articles and Media Coverage

• Finding Your Best Treatment Options for Lung Cancer Webinar, featuring Drs. Richard Battafarano and Julie Brahmer. Recorded Nov. 9, 2015

Research Interests

Development of anti-PD-1 antibodies, Drug development for thoracic malignancies and immunotherapy

Research Summary

Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma at SKCCC.  She is in charge organizing the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach.  She is also a part of the oncology pain team headed by Dr. Stuart Grossman.

PubMed

http://www.ncbi.nlm.nih.gov/sites/myncbi/1Nuc8xfUr5bAz/bibliography/48120579/public/?sort=date&direction=ascending

Selected Publications

• Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares, L, Reck M, Baudelet,C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2);123-35.

• Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MA, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL.  A Phase I Study of Single-Agent Anti-PD1 (MDX-1106) in Refractory Solid Tumors:  Safety, Clinical Activity, Pharmacodynamics and Immunological Correlates. J Clin Oncol, 2010; 28(19):3167-75.

• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM.  Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med 2012; 366(26):2455-65.

• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39.

• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, Activity and Immune Correlates of Anti-PD-1 Antibody in Cancer.  N Engl J Med 2012; 366(26):2443-54.

Memberships

• ACP
• ASCO
• IASLC
• American Association of Cancer Research (AACR)
• Society for Immunotherapy of Cancer (SITC)

Professional Activities

• Free to Breathe, Scientific Executive Committee
• Lung Cancer Foundation of America, Scientific Advisory Board
• Lung Cancer Research Foundation, Scientific Advisory Board
• Lungevity, Scientific Advisory Board